HomeProvidersServicesPatient InfoContact Us
Interested in Clinical Trials?
are you eligible?  
LUPUS Clinical Trial
HGS Benlysta
ClinicalTrials.gov
Protocol # HGS1006-C1113
for inclusion exclusion criteria

Start: May 2013 - current

A randomized, double-blind,
placebo-controlled 52-week study to
assess adverse events of special
interest adults with active,
autoantibody-positive Systemic
Lupus Erythematosus (SLE)
receiving Belimumab (Benlysta).

1) Male or Female > 18 years old  (female
subject Not pregnant or currently nursing, or
plan on being pregnant within the next 5 years)
2) Diagnosis of SLE
3) Active, autoantibody positive SLE
4)Are on a SLE treatment regimen -
corticosteroids and/or other immunomodulatory

For more information,
please call 925-413-1451  
Tim Davis,
Research Coordinator
Previously Completed Trials (2012-2015)
AstraZeneca TULIP1
ClinicalTrials.gov
Protocol # D3461C00005
for Inclusion Exclusion criteria

Start: September 2015 - current

A Multicentre, Randomised,
Double-blind,
Placebo-controlled, Phase 3
Study Evaluating the Efficacy
and Safety of Two Doses of

Anifrolumab
in Adult Subjects
with Active Systamic Lupus
Erythematosis (LUPUS)

Informed Consent (PDF-25 pages)
Flyer for potential subjects (coming soon)
2-Page inclusion-exclusion criteria - for
Providers

For more information,
please call 925-413-1451
 
Tim Davis,
Research Coordinator
Axial Spondyloarthritis Clinical Trial
Janssen Ustekinumab (Stelara)

ClinicalTrials.gov
Protocol # CNTO1275AKS3002
for inclusion exclusion criteria

Start: December 2015 - Current

A Study to Evaluate the Efficacy and Safety of
Ustekinumab in the Treatment of
Anti-TNF(Alpha) Refractory Participants With
Active Radiographic Axial Spondyloarthritis

Informed Consent (PDF-38 pages)
Flyer (3 fold- 2 page PDF) - for potential subjects
2 page inclusion-exclusion criteria - for Providers

For more information,
please call 510-791-1300  
ask for Victor or Richelle,
Research Coordinator
Currently we are recruiting for the following studies:
1.
Lupus (SLE) (2 different studies)
2. Axial Spondyloarthritis
3. Psoriatic Arthritis
CONTACT US: Tel: 510-791-1300   Fax: 510-791-1301
3775 Beacon Ave, Suite 100, Fremont, CA 94538   
A Cross-sectional Observational Study Evaluating Clinical
Specialty Setting as Determinant of Management in Patients
with Psoriatic Arthritis  (Start 2016 June- Dec)

Informed Consent (9 pages)
California Experimental Subject's Bill of Rights (1 page)

Study #: H15-457
Sponsor: AbbVie
Study Doctor: Barry Shibuya MD

Qualification: You have either been diagnosed in the past with psoriatic Arthritis (PsA),
suspected to have PsA or newly diagnosed with PsA.
Note: this study does not replace your regular medical care.


Purpose of the Study
The purpose of this study is to evaluate the role of different physician specialties
(Rheumatologist, Dermatologist, and Primary Care Physician) in the management of PsA.

This study is being conducted at approximately 60 research centers in the US. Approximately
1040 patients with suspected or newly diagnosed PsA or PsA diagnosed in the past will
participate in this study.

Your participation in this study will consist of 2 study visits.  You will have one visit at a
Rheumatology research center and one visit at a Dermatology research center. Your
participation in the study will last approximately 6 weeks but could be longer depending on
the time to complete PsA diagnostic testing and the availability of the study doctor for the
second visit.

For more information, please call 510-791-1300  
ask for Victor or Richelle,
Research Coordinator
Fremont Rheumatology
Arthritis, Osteoporosis, and Auto-Immune Diseases
Barry Shibuya M.D.  and  Christine Elias M.D.